cougar-web-cscc

Et et enim, suscipit aliquet pellentesque ornare massa. Volutpat congue mauris eget egestas massa nibh faucibus.

Suspendisse ullamcorper pellentesque quis mi malesuada. Luctus facilisi blandit urna leo, dignissim volutpat. Semper
http://clevelandbanner.com/stories/2-cols-2-lines-cscc-falls-to-snead,86536
CSCC VB falls to Snead | The Cleveland Daily Banner
The Cleveland State Community College women's volleyball team lost to Snead State in straight sets on the road Wednesday night.It was a back-and-forth game for both teams, with the Lady Cougars
Visit Link
https://library.cscc.edu/techtips/print
Print - Technology Tips - Library at Columbus State Community College
This guide provides answers to some of the most frequently asked, technology-based questions at the library. This page contains information regarding printing services and troubleshooting.
Visit Link
http://www.cscc.edu/academics/tuition-and-fees/disbursement.shtml
Disbursement | Columbus State Community College
A community college in Columbus, Ohio. You can earn a two-year technical degree, or complete the first two years of your bachelor's degree. We also offer noncredit training, ESL, GED and other services. With an open enrollment policy and the lowest tuition cost in the area, Columbus State is where t...
Visit Link
http://www.cscc.edu/academics/calendar/autumn-semester.shtml
Autumn Semester | Columbus State Community College
A community college in Columbus, Ohio. You can earn a two-year technical degree, or complete the first two years of your bachelor's degree. We also offer noncredit training, ESL, GED and other services. With an open enrollment policy and the lowest tuition cost in the area, Columbus State is where t...
Visit Link
https://www.onclive.com/web-exclusives/fda-approves-cemiplimab-for-cscc
FDA Approves Cemiplimab for CSCC
The FDA has approved the PD-1 inhibitor cemiplimab (Libtayo) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.  
Visit Link
https://www.onclive.com/web-exclusives/positive-topline-results-announced-for-cemiplimab-in-advanced-cscc
Positive Topline Results Announced for Cemiplimab in Advanced CSCC
Results from EMPOWER-CSCC 1 showed that cemiplimab (REGN2810) induced an overall response rate of 46.3% in patients with advanced cutaneous squamous cell carcinoma.
Visit Link
https://www.onclive.com/web-exclusives/immunotherapy-approval-offers-new-hope-in-cscc
Immunotherapy Approval Offers New Hope in CSCC
Treatment for cutaneous squamous cell carcinoma (CSCC) took a great leap forward in September 2018 with the PD-1 inhibitor cemiplimab becoming the first agent specifically approved by the FDA for advanced CSCC.
Visit Link
https://www.onclive.com/web-exclusives/fda-grants-priority-review-to-cemiplimab-in-cscc
FDA Grants Priority Review to Cemiplimab in CSCC
The FDA has granted a priority review to a biologics license application for the PD-1 inhibitor cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not eligible for surgery.  
Visit Link